In This Article:
NEW YORK, NY / ACCESSWIRE / July 6, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Endo International Plc (ENDP)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/endo-international-plc-loss-submission-form?prid=7796&wire=1
Lead Plaintiff Deadline: August 18, 2020
Class Period: August 8, 2017 - June 10, 2020
Allegations against ENDP include that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Co-Diagnostics, Inc. (CODX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/co-diagnostics-inc-loss-submission-form?prid=7796&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: February 25, 2020 - May 15, 2020
According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company's main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics' stock while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics' fraudulent misstatements displayed a disregard for basic scientific principles and caused investors to lose millions of dollars.
Ideanomics, Inc. (IDEX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ideanomics-inc-loss-submission-form?prid=7796&wire=1
Lead Plaintiff Deadline: August 27, 2020
Class Period: March 20, 2020 - June 25, 2020
Allegations against IDEX include that: (i) Ideanomics' Mobile Energy Global Division in Qingdao, China (the "MEG Center") was not "a one million square foot EV expo center" as the Company had stated in press releases; (ii) the Company had been using doctored or altered photographs of the purported MEG Center in Qingdao; (iii) the Company's electric vehicle business in China was not performing nearly as strongly as Ideanomics had represented; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.